{"schema_version":"secwatch.filing_event.v1","accession":"0001326190-24-000027","form_type":"8-K","ticker":"ALT","cik":"0001326190","company_name":"Altimmune, Inc.","filed_at":"2024-08-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:12.610127+00:00","generated_at":"2026-05-31T10:44:19.892016+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Altimmune Q2 net loss $24.6M; pemvidutide MASH Phase 2b topline due Q1 2025","bullets":["Cash, cash equivalents and short-term investments totaled $164.9M as of June 30, 2024.","Net loss for Q2 2024 was $24.6M ($0.35 per share) vs. $16.1M ($0.32 per share) in Q2 2023.","Phase 2b IMPACT trial of pemvidutide in MASH enrollment progressing; topline data expected Q1 2025.","End-of-Phase 2 FDA meeting for obesity program expected late Q3 2024 to discuss Phase 3 design.","Phase 2 MOMENTUM obesity trial showed up to 15.6% weight loss at 48 weeks and class-leading lean mass preservation."],"urls":{"canonical":"https://secwatch.observer/filing/0001326190-24-000027","json":"https://secwatch.observer/filing/0001326190-24-000027.json","markdown":"https://secwatch.observer/filing/0001326190-24-000027.md","text":"https://secwatch.observer/filing/0001326190-24-000027.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1326190/000132619024000027/0001326190-24-000027-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1326190/000132619024000027/alt-20240808x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T10:44:19.892016+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}